Speaker illustration

Doctor Muthiah Vaduganathan

Brigham And Women'S Hospital, Harvard Medical School, Boston (United States of America)

Member of:

European Society of Cardiology

Dr. Vaduganathan is a cardiologist and clinical trialist at Brigham and Women’s Hospital and Harvard Medical School. He is co-director of the Center for Cardiometabolic Implementation Science at Brigham and Women’s Hospital. He is a co-chair of a Heart Failure Collaboratory committee focused on improving future clinical trials in heart failure, and serves on the planning committee of the Global CardioVascular Clinical Trialists Forum. He is a Section Editor of the Fellows-in-Training / Early Career section of JACC, Associate Editor of JACC Heart Failure, and serves on the editorial board of the European Journal of Heart Failure. His research focuses on drug development, clinical trials, and implementation of cardio-renal-metabolic therapies, and he has authored or co-authored more than 500 peer-reviewed publications. He participates on study leadership and on committees of ongoing advanced-phase trials in cardiometabolic medicine and heart failure.

A Pre-Specified Meta-Analysis of DELIVER and EMPEROR-Preserved.

Event: ESC Congress 2022

Topic: Pharmacotherapy

Session: HOT LINE SESSION 4

Thumbnail

Interactive panel discussion and conclusion.

Event: Heart Failure 2022

Topic: Chronic Heart Failure

Session: Atrial fibrillation (AF) and heart failure (HF): future perspectives to improve patients outcomes

Thumbnail

Rhythm control in patients with AF and concomitant HF: current concepts and future perspectives.

Event: Heart Failure 2022

Topic: Chronic Heart Failure

Session: Atrial fibrillation (AF) and heart failure (HF): future perspectives to improve patients outcomes

Thumbnail

Estimating composite benefits of combination medical therapy in heart failure with mildly reduced and preserved ejection fraction

Event: Heart Failure 2022

Topic: Heart Failure with Mid-Range Ejection Fraction (HFmrEF)

Session: Imaging in chronic heart failure

Thumbnail

Effects of steroidal mineralocorticoid receptor antagonists on acute and chronic estimated glomerular filtration rate slopes in patients with chronic heart failure

Event: Heart Failure 2022

Topic: Pharmacotherapy

Session: Heart Failure ePosters - focus on Chronic Heart Failure 8

Thumbnail

Health status trajectories before and after hospitalization for heart failure

Event: Heart Failure 2022

Topic: Epidemiology, Prognosis, Outcome

Session: Heart failure patient profile and outcome 1

Thumbnail

The value of NT-proBNP in cardiovascular risk stratification and optimization of cardioprotective treatment among patients with type 2 diabetes.

Event: ESC Congress 2021 - The Digital Experience

Topic: Biomarkers

Session: Cardiac biomarkers are here to stay

Thumbnail

SGLT2 inhibitors in action.

Event: ESC Congress 2021 - The Digital Experience

Topic: Chronic Heart Failure

Session: SGLT2 inhibitors and heart failure in the cardiorenal spectrum

Thumbnail

SGLT2 Inhibitors as a Central Cardio-Renal-Metabolic Therapy: The Modern Day ACE Inhibitor.

Event: ESC Congress 2021 - The Digital Experience

Topic: Chronic Heart Failure

Session: SGLT2 inhibitors and heart failure in the cardiorenal spectrum

Thumbnail

Rivaroxaban and stroke events in patients with heart failure, sinus rhythm, and coronary disease: the COMMANDER-HF trial

Event: Heart Failure 2019 - 6th World Congress on Acute Heart Failure

Topic: Pharmacotherapy

Session: Late breaking trial II - Chronic heart failure

Thumbnail

ESC 365 is supported by

logo Novo Nordisk